Targeted therapy of non-small-cell lung carcinoma. - Wikidata - wikimedia - TriplyDB

Targeted therapy of non-small-cell lung carcinoma.

Targeted therapy of non-small-cell lung carcinoma.

http://www.wikidata.org/entity/Q37897792

about

Overall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data.

P2860

Q30588681-CF0A941C-7056-47AF-99D5-1D260746FBFA

P2860

Targeted therapy of non-small-cell lung carcinoma.

http://www.wikidata.org/entity/Q37897792

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 05 July 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeted therapy of non-small-cell lung carcinoma.

@en

Targeted therapy of non-small-cell lung carcinoma.

@nl

type

label

Targeted therapy of non-small-cell lung carcinoma.

@en

Targeted therapy of non-small-cell lung carcinoma.

@nl

prefLabel

Targeted therapy of non-small-cell lung carcinoma.

@en

Targeted therapy of non-small-cell lung carcinoma.

@nl

P1433

Q37897792-C4768040-E833-4D6B-8FDB-E754956EE1C0

P1476

Q37897792-86D916EF-D23C-4D47-BFC4-1753BB43FC24

P2093

Q37897792-7B09E667-43BF-4DD7-A6B9-A9C8F9A1F9CD

Q37897792-9ED1924B-FB85-4B61-BB9F-72CA7EC20771

P2860

Q37897792-03BDD3E7-307E-4EDD-8EEC-E19BF90EEBDC

Q37897792-0771667D-CC54-4FF5-8457-D561478D1EEC

Q37897792-0791BB55-B103-4359-9D90-4F2491CFF937

Q37897792-08E16E20-1D18-4F9B-8E7A-00D621E7E579

Q37897792-0A24D430-A91C-4B3E-9776-4D04A9841224

Q37897792-0DE50B57-1BD4-408B-A8BD-69534F78722F

Q37897792-166C6D8A-EC88-4F50-A1A6-344B6D371F69

Q37897792-182CAFFA-7543-4D77-8714-5A044D7E8D6E

Q37897792-1FBB705E-86FD-4732-9CDD-18EB48705A5C

Q37897792-23406447-BC92-493D-82B2-2EA73306E1F9

P304

Q37897792-138F1447-0F91-4249-BBB4-FC77E045FF86

P31

Q37897792-0B261F98-14AA-4150-99EE-C1294A80EA85

P356

Q37897792-875F4047-277E-45D5-981D-F5C265145360

P433

Q37897792-3FEAEB18-B7B8-4808-95BA-338BE090BB9B

P478

Q37897792-241E96B0-F6E7-422C-AAB1-02955F33170B

P50

Q37897792-B6C8DF64-568C-4EB6-8919-ACCE10B7B59E

P577

Q37897792-5EED278D-D5C9-4E3C-95AF-7D21866A5155

P698

Q37897792-A366D7F5-7567-4D2D-AD0C-A3E869CCF6CD

P356

1753465811404590

P1433

Therapeutic advances in respiratory disease

P1476

Targeted therapy of non-small-cell lung carcinoma

@en

P2093

Divya Tiwari

http://www.w3.org/2001/XMLSchema#string

Seth A Brodie

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.

P304

41-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1753465811404590

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Johann C. Brandes

P577

2011-07-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21730004

http://www.w3.org/2001/XMLSchema#string